{"DataElement":{"publicId":"5633321","version":"1","preferredName":"Prior Therapeutic Procedure Receive Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response to determine patient eligibility for clinical trial participation as outlined in the protocol for questions related to the prior administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"PRTX_RCD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"5633319","version":"1","preferredName":"Prior Therapeutic Procedure Receive Clinical Trial Eligibility Criteria","preferredDefinition":"Earlier in time or order._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._To take, accept, or get something offered._Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"3693401v1.0:5633317v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"3693401","version":"1","preferredName":"Prior Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D743B17B-E51D-394C-E040-BB89AD4312FF","latestVersionIndicator":"Yes","beginDate":"2013-03-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2013-03-06","modifiedBy":"ONEDATA","dateModified":"2013-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5633317","version":"1","preferredName":"Receive Clinical Trial Eligibility Criteria","preferredDefinition":"To take, accept, or get something offered.:Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C25639:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DF1A74-5127-7E36-E053-F662850A92C5","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"ONEDATA","dateModified":"2017-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DF1A74-5138-7E36-E053-F662850A92C5","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"SOKKERL","dateModified":"2017-01-26","changeDescription":"1/24/17 tt 10007","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]}],"AlternateNames":[{"name":"Theradex","type":"USED_BY","context":"Theradex"},{"name":"NRG","type":"USED_BY","context":"NRG"},{"name":"PR_TX_CD_IND","type":"OID, Theradex","context":"Theradex"}],"ReferenceDocuments":[{"name":"Has patient received prior th","type":"Preferred Question Text","description":"Has patient received prior therapy with selumetinib or another specific MEK inhibitor or prior MEK, RAS or RAF inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Has patient received cytoreduction with hydroxyurea, 6-mercaptopurine, dexamethasone or cyclophosphamide within at least three days prior to the initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient received prior treatment with a PARP inhibitor or topotecan?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Has patient received prior treatment with tyrosine kinase inhibitors (e.g. erlotinib), or anti-EGFR agents (e.g. cetuximab, pamatumamab)?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"If patient has PHEO/PGL with germline SDH subunit mutation, has patient received prior therapy with 131I-MIBG (in patients with MIBG avid tumors) or cytotoxic chemotherapy (CVD or temozolomide)?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Has patient received prior MEK, RAS, or RAF inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Has patient received prior therapy with viral-based tumor vaccine?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"If patient is enrolled in Phase II: Has patient received prior treatment with a TORC1, dual TORC1/2 inhibitor, or BCL-2/xL inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient received prior treatment with an MDM2 inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has patient received prior therapy with bevacizumab, ramucirumab or any PARP inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient received prior therapy less than or equal to 4 weeks or, if known 5 half-lives of the prior agent (whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment)?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Has patient received prior therapy less than or equal to 4 weeks or, if known agent (whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment)?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Has patient received prior therapy with bevacizumab, ramucirumab or any PARP inhibitor, including olaparib?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Has pateint received prior therapy with enzalutamidede or phenobarbital within 5 weeks prior to cycle 1 day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Has patient received cytoreduction with hydroxyurea, 6-mercaptopurine, corticosteroids (dexamethasone prednisone or similar) or cyclophosphamide within at least three days prior to the initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has patient received prior treatment with tyrosine kinase inhibitors (e.g. erlotinib), or anti-EGFR agents (e.g. cetuximab, panitumumab)?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Has patient received prior treatment with an MEK inhibitor or an ERK inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has patient received cytoreduction with hydroxyurea, 6-mercaptopurine, corticosteroids (dexamethasone prednisone or similar) or cyclophosphamide within at least three days prior to the initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Has patient received prior treatment with cabozantinib?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Has patient received prior treatment with PI3K/AKT inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Has patient received prior treatment with Wee1 kinase inhibition?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Has patient previously received gemcitabine plus oxaliplatin therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Has patient had prior treatment with olaparib or other PARP1?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"If patient is enrolled to the randomized phase II portion, has patient received prior treatment with a CDK4/6 inhibitor or fulvestrant, or a PI3K inhibitor in the metastatic setting?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Has patient received cytoreduction with hydroxyurea, 6-mercaptopurine, corticosteroids (dexamethasone prednisone or similar) or cyclophosphamide within at least 24 hours prior to the initiation of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"If patient has received prior Docetaxel (or other taxane therapy) in the advanced setting (for the dose escalation cohort only), is patient anticipated to have maintained taxane sensitivity and in the opinion of the investigator would still benefit from further docetaxel therapy.","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Has patient had prior treatment with olaparib or other PARPi?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Has patient received prior treatment with platinum-containing regimen or ATR inhibitor for prostate cancer?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Has patient received prior treatment with radium-223?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Has patient received prior chemotherapy to treat the glioma?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Has patient had prior treatment with olaparib or any other PARPi?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Has patient received prior chemotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Has patient received prior treatment with MLN4924 (pevonedistat), azacitidine, or decitabine?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Has patient received prior treatment with radium-223, olaparib or other PARPi?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Has patient received more than 4 prior systemic chemotherapy-based agents?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Has patient received prior chemotherapy for AML, excluding hydroxyurea for count control, or ATRA for APML that was initially suspected but later ruled out?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Was patient previously treated on this study?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"If enrolled in Phase 2, has patient received prior chemotherapy for NSCLC?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Has patient been previously treated with MLN9708 (ixazomib)?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Does patient have a prior treatment history with fulvestrant or a PI3K inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient received prior treatment with any EGFR TKI?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Has patient had any prior treatment with XL184 (cabozantinib), any MET-targeting TKI, or any MET-targeting monoclonal antibody (MetMAb), such as onartuzumab?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Has patient received prior topotecan therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Has patient received any previous treatment with any poly (adenosine diphosphate[ADP]-ribose) polymerase (PARP) inhibitors, including olaparib, or prior treatment with dacarbazine and/or temozolomide?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Has patient received at least 2 lines of prior therapy (including at least one PI, excluding MLN9708), or has received 1 prior line of therapy with both a PI (excluding MLN9708) and an immunomodulatory (IMiD) agent?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Has patient received any previous treatment with AZD6738 or any other ATR inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"If patient is enrolled to the randomized Phase 2 portion of this study, has patient received prior treatment with a CDK4/6 inhibitor or fulvestrant, or a PI3K inhibitor in the metastatic setting?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Has patient been previously treated with platinum chemotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Has patient received prior treatment with MEC?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Has patient received prior therapy with radionuclides (e.g., strontium, samarium, rhenium, radium)?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Has patient received prior treatment with XL184 (cabozantinib), or any MET-targeting TKI, or any MET-targeting monoclonal antibody (MetMAb), such as onartuzumab?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"If patient is enrolled to the non-BRD4 exploratory cohort: did the patient previously receive treatment with a BETi, including but not limited to previous GSK525762C therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Has patient received at least one prior therapy for their condition prior to study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Has patient received a known CYP3A4 substrate with narrow therapeutic window (such as alfentanil, astemizole, cisapride, dihydroergotamine, pinozide; quinidine, sirolimus or terfanide) within 14 days prior to receiving the first dose of KRT-232 (AMG 232)?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Has patient received prior therapy with radionuclides (e.g., strontium, samarium, rhenium, radium)?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Has patient received at least one prior line of platinum-based chemotherapy?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Has patient received prior systemic chemotherapy or immunotherapy for metastatic disease?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Has patient received prior treatment with P13K, AKT, dual P13IK/mTOR inhibitors, TORC 1/ 2 inhibitors or TORC1 inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Has the patient received prior treatment with an anthracycline and taxane in the neoadjuvant, adjuvant, or metastatic setting, unless contraindicated or deemed to be suboptimal therapy per the treating physician?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"If patient has received prior treatment with anti-CTLA-4, have the following criteria been met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and greater than 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"If patient has received prior treatment with anti-CTLA-4, have the following criteria been met: Minimum of 12 weeks from the first dose of anti-CTLA-4 and 6 weeks from the last dose and no history of severe immune-related adverse effects from anti-CTLA-4 (NCI CTCAE Grade 3 and 4)?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Has patient received prior treatment with ATR inhibitor (prior BAY 1895344 or other investigational ATR inhibitors)?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"Does patient have a history of prior treatment with an ATR inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Has patient received prior treatment with any of the study compounds?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"If patient is enrolled in the safety run-in cohort, has patient received prior XL184 (cabozantinib), PD-1/PD-L1 inhibitor, or VEGFR inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"Has patient received prior treatment with talazoparib?","url":null,"context":"Theradex"},{"name":"NRG_CRFTEXT_1","type":"Alternate Question Text","description":"Prior or current treatment with PARP inhibitor?","url":null,"context":"NRG"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Has patient been previously treated with an ATR inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Has patient received prior treatment with Hu5F9-G4 (magrolimab) or any agent targeting CD47-SIRPa or prior treatment with mogamulizumab?","url":null,"context":"Theradex"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"Has patient received prior therapy with a P13K inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Has the patient received prior treatment with abemaciclib or another specific CDK4/6 inhibitor (ex., Ribociclib, Palbociclib Â– list is not all inclusive)?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"Has patient received prior CDK 4/6 inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Has patient received prior treatment with MLN9708 (ixazomib citrate) or venetoclax?","url":null,"context":"Theradex"},{"name":"Theradex - 73","type":"Alternate Question Text","description":"Has patient received prior treatment with MEK or ERK inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 72","type":"Alternate Question Text","description":"If patient is in the dose escalation and expansion phases, has patient received less than or equal to 5 lines of prior therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 74","type":"Alternate Question Text","description":"If patient is to be enrolled in Phase 1 and has received prior treatment with EP or ZEN003694, was dose reduction required due to unacceptable toxicities attributed to the agent(s)?","url":null,"context":"Theradex"},{"name":"Theradex - 77","type":"Alternate Question Text","description":"Has patient received prior treatment with a checkpoint inhibitor given for relapsed or metastatic disease?","url":null,"context":"Theradex"},{"name":"Theradex - 75","type":"Alternate Question Text","description":"Has patient received at least two previous therapies with at least one combination chemotherapy regimen for metastatic disease?","url":null,"context":"Theradex"},{"name":"Theradex - 78","type":"Alternate Question Text","description":"Has patient received prior treatment (e.g., chemotherapy, radiation, or definitive surgery) for the current locally advanced HNSCC?","url":null,"context":"Theradex"},{"name":"Theradex - 79","type":"Alternate Question Text","description":"If patient has lymphoma, at least two previous therapies with at least one combination chemotherapy regimen for metastatic disease?","url":null,"context":"Theradex"},{"name":"Theradex - 76","type":"Alternate Question Text","description":"Has patient received prior therapy with BET, RAF, MEK, or ERK inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 81","type":"Alternate Question Text","description":"Has patient previously been treated with BAY 1895344?","url":null,"context":"Theradex"},{"name":"Theradex - 80","type":"Alternate Question Text","description":"Has patient received prior treatment with neratinib or DS-8201a?","url":null,"context":"Theradex"},{"name":"Theradex - 82","type":"Alternate Question Text","description":"Has patient received prior treatment with ZEN003694 (ZEN-3694) or who have been treated with an investigational BET inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 84","type":"Alternate Question Text","description":"Has patient received any prior therapy aside from resection or biopsy for their recurrent disease?","url":null,"context":"Theradex"},{"name":"Theradex - 85","type":"Alternate Question Text","description":"Has patient previously received ZEN003694 (ZEN-3694) or has been treated with an investigational BET inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 86","type":"Alternate Question Text","description":"Has patient received treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Was levocarnitine started prior to first dose of asparaginase?","url":null,"context":"COG"},{"name":"Theradex - 87","type":"Alternate Question Text","description":"For dose escalation: Has patient previously received temozolomide or an ATR inhibitor?","url":null,"context":"Theradex"},{"name":"Theradex - 88","type":"Alternate Question Text","description":"Has patient received at least one prior line of platinum-based systemic therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 89","type":"Alternate Question Text","description":"Has patient been treated with at least 1 prior line of therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 90","type":"Alternate Question Text","description":"Has patient received prior anti-TIGIT therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 91","type":"Alternate Question Text","description":"Has patient received previous anti-CD47 therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 92","type":"Alternate Question Text","description":"Has patient had prior treatment with BET inhibitors?","url":null,"context":"Theradex"},{"name":"Theradex - 93","type":"Alternate Question Text","description":"Has patient received prior treatment with 2GAA and taxane- or Lutetium-based therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 94","type":"Alternate Question Text","description":"If patient has myelodysplastic syndromes (MDS), has patient received prior induction regimens similar to 7+3?","url":null,"context":"Theradex"},{"name":"Theradex - 96","type":"Alternate Question Text","description":"Has patient received previous rituximab therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 97","type":"Alternate Question Text","description":"Has patient failed 1 line of therapy or received prior CAR T therapy?","url":null,"context":"Theradex"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Has patient responded (defined as CR or PR or SD with clinical benefit on any post-CAR T cell infusion evaluation) to GD2CART therapy who later develop progressive disease if agreed upon by the PEP-CTN, Protocol Principal Investigator and CTEP","url":null,"context":"COG"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"46DF2B16-0FAA-0BC5-E053-F662850A78CE","latestVersionIndicator":"Yes","beginDate":"2017-01-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-01-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":"2020-8-3 AQT added for P10398. AK 1/25/17 tt 10007","administrativeNotes":"2023.9.18 AQT added per ticket request CADSR0002860. ak 2022.11.14 AQT added for ticket request CADSR0001676. ak","unresolvedIssues":null,"deletedIndicator":"No"}}